Flash Finance

Fredun Pharmaceuticals Ltd539730Corporate

Pharmaceuticals Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹1,221.60
MCap ₹611 Cr · P/E 13.8
Fredun Pharmaceuticals Ltd — Stock analysis & AI research Fredun Pharmaceuticals Ltd — Multibagger AI analysis Fredun Pharmaceuticals Ltd — Live exchange announcements
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹228 Cr
Sales · Jun 2026
+90.2% YoY
₹33 Cr
Operating Profit · Jun 2026
+92.8% YoY
14.4%
OPM % · Jun 2026
+1.4% YoY
₹13 Cr
Net Profit · Jun 2026
+88.1% YoY
₹23.89
EPS · Jun 2026
+400.8% YoY

📝 Fredun Pharmaceuticals Ltd — results explained

Quarter ended June 2026 (Q1 FY27)

Fredun Pharmaceuticals Ltd reported revenue of ₹228 crore for the quarter ended June 2026 (Q1 FY27), up 90.2% from ₹120 crore in the same quarter last year, and up 7.2% sequentially over the March 2026 quarter.

Net profit rose 88.1% year-on-year to ₹13 crore, from ₹7 crore. Earnings per share (EPS) came in at ₹23.89.

Operating profit stood at ₹33 crore — an operating margin (OPM) of 14.4%, compared with 14.2% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Fredun Pharmaceuticals Ltd posted revenue of ₹639 crore, a growth of 40.1% over FY25, with a net profit of ₹38 crore (up 90.0% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹747 crore with a net profit of ₹44 crore.

Valuation snapshot

At the current price of ₹1,221.60, 539730 has a market capitalisation of ₹611 crore and a trailing P/E of about 13.8.

Within the Pharmaceuticals industry, it is the 12th-largest of the 82 companies we track by market value.

Shareholding pattern

As of Jul 2026, promoters held 44.57%, foreign institutional investors (FIIs) 1.06%, domestic institutional investors (DIIs) 2.94%, public shareholders 51.43% of Fredun Pharmaceuticals Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹611 Cr
Current Price ?
₹1,221.6
P/E ?
13.83below ind
Industry P/E ?
22.40
P/B ?
2.20
P/S ?
0.82
P/FCF ?
-10.72
Enterprise Value ?
₹833 Cr
EV/EBITDA ?
7.59
PEG ?
0.31
Earnings Yield ?
11.9%
Dividend Yield ?
0.02%
Profitability & Returns
Sales (TTM) ?
₹747 Cr
OPM ?
14.7%
Profit after tax (TTM) ?
₹44 Cr
EPS (TTM) ?
₹88.34
ROCE ?
21.0%
ROE ?
15.9%
ROA ?
6.9%
Growth
Sales — latest qtr ?
₹228 Cr
PAT — latest qtr ?
₹13 Cr
YoY qtr sales growth ?
90.2%
YoY qtr profit growth ?
88.1%
Sales growth (3y) ?
32%
Sales growth (5y) ?
37%
Profit growth (3y) ?
45%
Profit growth (5y) ?
75%
Financial Health
Debt ?
₹222 Cr
Debt to Equity ?
0.80
Interest Coverage ?
2.1
Current Ratio ?
N/A
Ownership
Promoter holding ?
44.57%
Change in promoter holding ?
1.51%
Pledged percentage ?
N/A
Market
Return 3 months ?
40.1%
Return 6 months ?
122.0%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 8062828711879107103167120145161213228 +90.2% +7.2%
Operating Profit 128101111101413171722262933 +92.8% +13.0%
Other Income 0000000000000— — —
Interest 4334445587811149 +23.1% -38.4%
Depreciation 11111111112234 +257.1% +19.0%
Profit Before Tax 846666878913141221 +128.8% +71.6%
Net Profit 424454457710101113 +88.1% +19.7%
EPS 2.861.752.792.993.592.913.013.754.984.776.856.516.7523.89 +400.8% +253.9%
OPM % 15.0% 12.9% 12.2% 12.6% 9.3% 12.7% 13.1% 12.6% 10.2% 14.2% 15.2% 16.1% 13.6% 14.4% +1.4% +5.9%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹456 Cr ₹639 Cr ₹747 Cr +40.1%
Operating Profit ₹54 Cr ₹94 Cr ₹110 Cr +74.1%
OPM % 11.84% 14.71% 14.69% +24.2%
NPM % 4.39% 5.95% 5.91% +35.5%
Other Income ₹0 Cr ₹0 Cr ₹0 Cr —
Depreciation ₹4 Cr ₹8 Cr ₹11 Cr +100.0%
Interest ₹22 Cr ₹40 Cr ₹42 Cr +81.8%
EBIT ₹50 Cr ₹86 Cr ₹99 Cr +72.0%
PBT ₹29 Cr ₹48 Cr ₹60 Cr +65.5%
Tax — — — —
Net Profit ₹20 Cr ₹38 Cr ₹44 Cr +90.0%
EPS ₹14.65 ₹24.88 ₹44.00 +69.8%
Material Cost — — ₹180 Cr —
Employee Cost — — ₹7 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 5555 +0.0%
Reserves 92117137273 +99.3%
Borrowings 87106166222 +33.7%
Other Liabilities 7481179141 -21.2%
Total Liabilities 257308487642 +31.8%
Fixed Assets 394753118 +122.6%
CWIP 0000 —
Investments 0122 +0.0%
Other Assets 218260433522 +20.6%
Total Assets 257308487642 +31.8%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -14-0-2116 +176.2%
Cash from Investing Activity -9-8-6-74 -1133.3%
Cash from Financing Activity 25626122 +369.2%
Net Cash Flow 1-2-165 +6600.0%
Free Cash Flow -24-8-27-57 -111.1%
CFO/OP -52%-1%-43%18% +141.9%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 466814253 -62.7%
Inventory Days 264246267219 -18.0%
Days Payable 1048816171 -55.9%
Cash Conversion Cycle 205225248201 -19.0%
Working Capital Days 97927679 +3.9%
ROCE % 18%17%19%21% +10.5%

👥 Shareholding (latest 4 periods)

Metric Dec 2025Mar 2026Jun 2026Jul 2026 % Chg
Promoters 43.06%44.17%44.57%44.57% +0.0%
FIIs 0.46%1.06%1.06%1.06% +0.0%
DIIs 3.48%2.83%2.94%2.94% +0.0%
Public 53.00%51.94%51.45%51.43% -0.0%
No. of Shareholders 8,7658,3388,9039,598 +7.8%

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 82 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUDEEPPHRM Sudeep Pharma ₹1,033.30 11,671 63.3 675 184 34.6% 27.3% — — 26.6% 30.9%
2 SPARC Sun Pharma ₹185.08 6,006 3.8 1,909 1,584 84.7% 83.0% 2512.3% 553.9% 314.1% 59.9%
3 GUJTHEM Gujarat Themis ₹412.60 5,370 92.3 173 48 47.3% 27.8% 8.6% -6.1% 21.6% 23.0%
4 539997 Kwality Pharmaceuticals ₹2,652.10 3,525 34.0 553 81 24.4% 14.6% 35.7% 71.8% 46.3% 113.5%
5 524632 Shukra Pharmaceuticals ₹80.95 2,403 99.9 75 36 65.0% 48.2% 74.0% 130.1% 336.4% 1359.2%
6 FERMENTA Fermenta Biotech ₹475.00 1,362 21.4 501 64 18.9% 12.7% — — -17.9% -30.6%
7 506414 Fermenta Biotech ₹552.60 1,313 27.2 511 59 17.6% 11.5% 11.9% -6.6% -10.4% -56.7%
8 AHCL Anlon Healthcare ₹20.20 1,074 — — — — — — — 163.0% 133.3%
9 541096 Bharat Parenterals ₹1,525.00 1,062 — 323 -30 3.3% -9.3% 1.5% 37.5% -19.2% -309.6%
10 540737 Shree Ganesh ₹796.30 855 66.2 99 15 31.4% 15.6% 0.7% -23.0% -41.8% -67.5%
11 AMANTA Amanta Healthcare ₹197.75 768 52.5 291 15 20.4% 5.0% — — 5.4% -5.6%
12 539730 Fredun Pharmaceuticals ₹827.85 611 10.3 747 44 14.7% 5.9% 40.1% 90.0% 90.2% 88.1%
13 500422 Transchem Ltd-$ ₹38.00 474 10.8 — 4 — — -100.0% -17.8% -100.0% 186.3%
14 HALEOSLABS Haleos Labs ₹1,525.00 461 21.0 324 15 12.6% 4.7% -3.2% -4.9% -11.6% -58.0%
15 524731 Jenburkt Pharmaceuticals ₹865.75 404 11.6 170 33 23.6% 19.4% 11.8% 6.1% -1.4% -26.4%
16 543616 Trident Lifeline ₹279.85 364 14.0 134 24 24.6% 17.9% — — 42.6% 44.2%
17 512600 Astal Laboratories ₹75.00 308 32.3 170 10 8.8% 5.7% 142.9% -9.0% 56.0% 77.4%
18 524828 BDH Industries ₹336.80 300 16.6 100 12 15.3% 11.7% 44.3% 16.6% 20.2% 48.8%
19 500009 Ambalal Sarabhai ₹38.73 297 21.9 206 14 7.1% 6.6% 3.1% 261.1% 8.0% -51.6%
20 532039 Zenotech Laboratories ₹64.90 263 — 45 -3 17.0% -5.6% 1.3% -119.2% 10.1% -146.0%
21 531739 Gennex Laboratories ₹13.87 255 19.0 183 21 14.4% 11.3% 24.9% 15.5% 16.6% -6.9%
22 524790 Everest Organics ₹159.20 252 29.4 191 5 10.3% 2.8% 23.0% 527.7% -10.0% -21.1%
23 530163 Kerala Ayurveda ₹310.20 225 — 125 -26 -14.9% -20.8% 9.0% -16.8% -21.3% -477.8%
24 531569 Sanjivani Paranteral ₹199.95 214 32.7 66 7 15.3% 11.3% -7.6% -14.4% 8.8% 32.7%
25 524636 Oxygenta Pharmaceutical ₹32.25 195 — 135 -14 -5.9% -10.1% 3.3% -70.8% 144.5% 65.6%
❓ Frequently asked questions
What was Fredun Pharmaceuticals Ltd's revenue in Q1 FY27?
Fredun Pharmaceuticals Ltd reported revenue of ₹228 crore for the quarter ended June 2026 (Q1 FY27), up 90.2% from ₹120 crore in the same quarter last year, and up 7.2% sequentially over the March 2026 quarter.
What was Fredun Pharmaceuticals Ltd's net profit in Q1 FY27?
Net profit rose 88.1% year-on-year to ₹13 crore, from ₹7 crore. Earnings per share (EPS) came in at ₹23.89.
What is 539730's market capitalisation and P/E ratio?
At the current price of ₹1,221.60, 539730 has a market capitalisation of ₹611 crore and a trailing P/E of about 13.8.
Who owns Fredun Pharmaceuticals Ltd? (shareholding pattern)
As of Jul 2026, promoters held 44.57%, foreign institutional investors (FIIs) 1.06%, domestic institutional investors (DIIs) 2.94%, public shareholders 51.43% of Fredun Pharmaceuticals Ltd.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI